The weight loss community is abuzz with news of another potentially game-changing jab that could help people shed extra pounds. Tirzepatide, sold under the brand name Mounjaro, has produced impressive results in clinical trials, with participants losing an average of 34.4lbs (15.6kg). While it has only been approved for treating type 2 diabetes so far, some doctors in the US are prescribing it ‘off-label’ for weight loss. Several Americans, including Matthew Barlow and Caley Svensson, have already achieved substantial weight loss with Mounjaro. A recent trial found that tirzepatide was marginally more effective than its competitor, Wegovy, in helping people lose weight. The drug is still awaiting approval for weight loss in the UK and US, but Eli Lilly and Co, the manufacturer, is hopeful that it will receive approval soon. While the drug can have side effects such as nausea, diarrhea, and vomiting, it has been hailed for its potential to help people lose weight that is difficult to shift with diet and exercise alone.
